Lehel Simon
Entactex Pharma Research Project, Hungary
Title: Levente Szilágyi: An outlook on the genetics of autisms and analogue conditions from a cognitive science perspective and the possibility of a personalized polymer amine therapy
Biography
Biography: Lehel Simon
Abstract
Autisms have been examined from many aspects: as clinical description, by means of the nowadays popular cognitive psychology, from a brain anatomy aspect (see corpus callosum and hypothalamus lesion), as the subject of genetics (X - fragility) and from the gender aspect (see Asperger syndrome: “male brain disorder”). But scientist so far failed to even try to combine these models.
Clinical description can now be proven by cognitive psychology (see “Read the Mind” -tests) – this is a matter of fact. For example corpus callosum-lesion can be explained by this, and X-fragility can be explained by the gender relevancies of the aforementioned and so on.
A unified biochemical model has not been developed yet while the scientific media is loud about the oxytocin, secretin, ondansetron and naltrexone experiments. What are their common aspects in the nucleus suprachiasmaticus of the hypophysis? It has been suspected that this is where the resolution lies but we have not had a biochemical model.
The ultimate question in our study is as follows. Can a stable and healthy state of the hypothalamic balance be established in the nucleus suprachiasmaticus? We examine every brain research aspects of this from gender to neuro-biochemistry to make a futuristic suggestion which can be easily accomplished taking the modern drug technology into consideration by testing the applicableness of peptide operator polymer amines – focusing on the neuropeptides of hypothalamus.